8,906 results match your criteria Alimentary Pharmacology and Therapeutics[Journal]


Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.

Aliment Pharmacol Ther 2019 Apr 15. Epub 2019 Apr 15.

University of Melbourne, Parkville, Vic., Australia.

Background: Calcineurin-inhibitor immunosuppressants (tacrolimus and ciclosporin) have been associated with an exposure-related increase in tumour recurrence following liver transplantation for hepatocellular carcinoma (HCC). Conversely, mechanistic target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) have been suggested to reduce recurrence rates and improve survival in this patient group.

Aim: To clarify the potential benefit of mTOR-inhibitors in HCC transplant patients by comparing recurrence and survival outcomes with calcineurin-inhibitor-based immunosuppression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15253DOI Listing

Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease.

Aliment Pharmacol Ther 2019 Apr 15. Epub 2019 Apr 15.

Robarts Clinical Trials Inc, London, ON, Canada.

Background: The appropriate location for biopsy procurement relative to an ulcer in active Crohn's disease is unknown.

Aim: To explore the relationship between biopsy location, histological disease activity, proinflammatory gene expression and the presence of inflammatory cells.

Methods: Fifty-one patients with Crohn's disease and ulcers >0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15250DOI Listing

A nationwide cohort study of the incidence of microscopic colitis in Sweden.

Aliment Pharmacol Ther 2019 Apr 15. Epub 2019 Apr 15.

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Background: Epidemiological studies of microscopic colitis have shown varying but increasing incidence rates.

Aim: To assess the incidence of microscopic colitis in Sweden.

Methods: Nationwide cohort study performed in 1995-2015 based on biopsy reports. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15246
Publisher Site
http://dx.doi.org/10.1111/apt.15246DOI Listing
April 2019
1 Read

Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy.

Aliment Pharmacol Ther 2019 Apr 15. Epub 2019 Apr 15.

Centre for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India.

Background: CD4 regulatory T-cells (Tregs) expand during chronic hepatitis B virus (HBV) infection and inhibit antiviral immunity, although the underlying mechanism remains largely elusive. Myeloid-derived suppressor cells (MDSC) have been linked with T-cell dysfunction but questions remain regarding their persistence/profile/function in chronically HBV infected patients.

Aim: To characterise MDSC in different phases of chronic HBV infection namely, immune-tolerant (IT), hepatitis B e-antigen-positive chronic hepatitis B (EP-CHB), inactive carriers (IC) and hepatitis B e-antigen-negative chronic hepatitis B (EN-CHB), to investigate their role in Treg induction and evaluate the effect of anti-viral therapy on these cells. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15226
Publisher Site
http://dx.doi.org/10.1111/apt.15226DOI Listing
April 2019
2 Reads

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Aliment Pharmacol Ther 2019 Apr 12. Epub 2019 Apr 12.

Vienna, Austria.

Background: Programmed cell death protein-1-targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma.

Aim: To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real-world cohort of patients with advanced hepatocellular carcinoma.

Methods: Sixty-five patients treated with nivolumab (n = 34) or pembrolizumab (n = 31) between July 10, 2015 and December 31, 2018 (data cut-off) across six centres in Austria and Germany were retrospectively analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15245DOI Listing

Letter: HCV complication and type 2 diabetes management-the directional link is not yet defined. Authors' reply.

Authors:
Jia Li

Aliment Pharmacol Ther 2019 May;49(9):1251-1252

Department of Public Health Sciences, Henry Ford Health System, Detroit, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15247DOI Listing
May 2019
3 Reads

Editorial: post-operative elevation of liver enzymes and modern volatile anaesthetics-guilty as charged?

Aliment Pharmacol Ther 2019 May;49(9):1245-1246

Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15207DOI Listing

Letter: studies of salivary pepsin in patients with gastro-oesophageal reflux disease. Authors' reply.

Aliment Pharmacol Ther 2019 May;49(9):1249-1250

Department of Gastroenterology, Northern General Hospital, Sheffield, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15225DOI Listing

Studies of salivary pepsin in patients with gastro-oesophageal reflux disease.

Aliment Pharmacol Ther 2019 May;49(9):1173-1180

Department of Gastroenterology, Northern General Hospital, Sheffield, UK.

Background: Gastro-oesophageal reflux disease (GERD) is difficult to diagnose without invasive testing. Peptest (RD Biomed, Hull, UK) is a recently marketed diagnostic tool which aims to quantify salivary pepsin as a marker of reflux, providing a rapid alternative to invasive procedures.

Aim: To evaluate optimal timing for sampling, and to evaluate the accuracy of Peptest against an independent measure. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15138
Publisher Site
http://dx.doi.org/10.1111/apt.15138DOI Listing
May 2019
8 Reads

Editorial: post-operative elevation of liver enzymes and modern volatile anaesthetics-guilty as charged? Authors' reply.

Aliment Pharmacol Ther 2019 May;49(9):1246-1247

Departments of Anesthesiology and Critical Care Medicine, Pediatrics, and Pathology, Johns Hopkins University, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15237DOI Listing
May 2019
2 Reads

Editorial: breaking the cycle of cough in GERD-neuromodulators to the rescue?

Aliment Pharmacol Ther 2019 May;49(9):1242-1243

Division of Gastroenterology, Hepatology, and Nutrition, Center for Swallowing and Esophageal Disorders, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15205DOI Listing
May 2019
1 Read

Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply.

Aliment Pharmacol Ther 2019 May;49(9):1254-1255

Gastroenterology Division, McMaster University, Health Sciences Center, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15234DOI Listing

Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS.

Aliment Pharmacol Ther 2019 May;49(9):1253-1254

Department of Plastic Surgery, Affiliated Hospital of Qingdao University, Qingdao, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15230DOI Listing

Letter: HCV complication and type 2 diabetes management-the directional link is not yet defined.

Aliment Pharmacol Ther 2019 May;49(9):1250-1251

Indian Institute of Science Education and Research Bhopal, Bhopal, India.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15228
Publisher Site
http://dx.doi.org/10.1111/apt.15228DOI Listing
May 2019
1 Read

Editorial: breaking the cycle of cough in GERD-neuromodulators to the rescue? Authors' reply.

Aliment Pharmacol Ther 2019 May;49(9):1243-1244

Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15217DOI Listing
May 2019
3 Reads

Letter: studies of salivary pepsin in patients with gastro-oesophageal reflux disease.

Aliment Pharmacol Ther 2019 May;49(9):1248-1249

Institute for Cell and Molecular Biosciences, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15213
Publisher Site
http://dx.doi.org/10.1111/apt.15213DOI Listing
May 2019
1 Read

Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels.

Aliment Pharmacol Ther 2019 Apr 11. Epub 2019 Apr 11.

Sydney, NSW.

Background: Mycophenolate mofetil is a commonly used salvage therapy for patients with autoimmune hepatitis (AIH).

Aim: To evaluate the predictors of response to mycophenolate rescue therapy to facilitate clinical decision making.

Methods: We performed a retrospective observational cohort study of AIH patients managed in 17 major Australian liver centres who received mycophenolate after an inadequate response or intolerance to corticosteroids with/without thiopurine(s). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15248DOI Listing
April 2019
5.727 Impact Factor

Early and late mortality following unscheduled admissions for severe liver disease across England and Wales.

Aliment Pharmacol Ther 2019 Apr 11. Epub 2019 Apr 11.

Medical School, Swansea University, Swansea, UK.

Background: There is a known shortfall in hepatology service resources across England and Wales.

Aim: To investigate early and late mortality following unscheduled admissions for severe liver disease, overall and by cause of death, and to determine how mortality is related to admissions to transplant centres, transplant surgery, hospital size, consultant specialty, patient socio-demographics, seasonal and geographical factors.

Methods: Cohorts of people with a first unscheduled admission for severe liver disease across England and Wales from 2004, based on record linkage of national inpatient and mortality data. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15232
Publisher Site
http://dx.doi.org/10.1111/apt.15232DOI Listing
April 2019
4 Reads

Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients.

Aliment Pharmacol Ther 2019 Apr 8. Epub 2019 Apr 8.

Department of Clinical Sciences, Lund University, Lund, Sweden.

Background: Liver cirrhosis is characterized by a silent phase until decompensation, which is defined by ascites, bleeding from esophageal varices or hepatic encephalopathy.

Aim: We compare the clinical course, patterns of survival and causes of death by etiology during long-term follow-up in a large population-based cohort of patients with incident cirrhosis.

Material And Methods: We used population-based medical registries for a cohort study of patients with liver cirrhosis diagnosed January 2001 to December 2010, in the Scania region of Sweden. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15255
Publisher Site
http://dx.doi.org/10.1111/apt.15255DOI Listing
April 2019
8 Reads

Chronic continuous abdominal pain: evaluation of diagnostic features, iatrogenesis and drug treatments in a cohort of 103 patients.

Aliment Pharmacol Ther 2019 Apr 4. Epub 2019 Apr 4.

Gastroenterology, Salford Royal NHS Foundation Trust, Salford, UK.

Background: Chronic continuous abdominal pain (CCAP) is characteristic of centrally mediated gastrointestinal pain disorders. It consumes significant healthcare resources yet is poorly understood, with minimal cohort-specific data in the literature.

Aims: To examine in a large cohort of CCAP patients, (a) diagnostic features, (b) iatrogenic impact of opioids and surgery, (c) drug treatment effects and tolerance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15241DOI Listing
April 2019
1 Read

External validation of a model to determine risk of progression of Barrett's oesophagus to neoplasia.

Aliment Pharmacol Ther 2019 Apr 4. Epub 2019 Apr 4.

Cancer Epidemiology Research Group, Queen's University Belfast, Belfast, UK.

Background: A risk prediction model containing sex, smoking history, Barrett's oesophagus length and presence of low-grade dysplasia was found to identify individuals at a higher risk of progression to oesophageal adenocarcinoma or high-grade dysplasia.

Aim: To externally validate the model predicting risk of progression from Barrett's oesophagus to neoplasia and assess the predictive utility of additional factors.

Methods: We conducted a retrospective cohort study among individuals from the population-based Northern Ireland Barrett's register with a histologically confirmed diagnosis of Barrett's oesophagus (with intestinal metaplasia) between 1993 and 2005. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15235DOI Listing
April 2019
2 Reads

Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors.

Aliment Pharmacol Ther 2019 May 1;49(9):1195-1204. Epub 2019 Apr 1.

Liver Diseases Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.

Background: Bodybuilding supplements can cause a profound cholestatic syndrome.

Aim: To describe the drug-Induced liver injury network's experience with liver injury due to bodybuilding supplements.

Methods: Liver injury pattern, severity and outcomes, potential genetic associations, and exposure to anabolic steroids by product analysis were analysed in prospectively enrolled subjects with bodybuilding supplement-induced liver injury with causality scores of probable or higher. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15211DOI Listing
May 2019
2 Reads

Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.

Aliment Pharmacol Ther 2019 May 1;49(9):1181-1187. Epub 2019 Apr 1.

Nancy University Hospital, Vandœuvre-lès-Nancy, France.

Background: The nocebo effect is a negative effect of a pharmacological or nonpharmacological medical treatment that is induced by patients' expectations, and that is unrelated to the physiological action of the treatment. The nocebo effect can negatively affect treatment outcomes.

Aim: To develop evidence-based consensus recommendations for the prevention and management of the nocebo effect in biosimilar-treated patients with IBD. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15223
Publisher Site
http://dx.doi.org/10.1111/apt.15223DOI Listing
May 2019
4 Reads

The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection.

Aliment Pharmacol Ther 2019 Apr 1. Epub 2019 Apr 1.

Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety, Michael E DeBakey VA Medical Center, Houston, Texas.

Background: Direct-acting anti-viral (DAA) therapy may have a beneficial role in extrahepatic manifestations of hepatitis C virus (HCV) infection. However, the available data are limited.

Aim: To examine the effects of DAA treatment on the risk of several extrahepatic manifestations of HCV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15240DOI Listing
April 2019
3 Reads

Review article: treatment options for functional dyspepsia.

Aliment Pharmacol Ther 2019 May 28;49(9):1134-1172. Epub 2019 Mar 28.

Translational Research Centre for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium.

Background: Functional dyspepsia, consisting of epigastric pain syndrome and postprandial distress syndrome, is a prevalent functional gastrointestinal disorder. To date, only limited treatment options are available and conflicting results in terms of efficacy have been reported. Consequently, nonpharmacological treatment options are increasingly being explored for functional dyspepsia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15191DOI Listing
May 2019
1 Read

Letters: low FODMAP diet-directions for future research and the low FODMAP diet is not the only diet for IBS-authors' reply.

Aliment Pharmacol Ther 2019 Apr;49(8):1109-1110

Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15199DOI Listing
April 2019
1 Read

Editorial: you bet your life - medication risk taking by gastroparesis patients in a hypothetical exercise.

Authors:
William L Hasler

Aliment Pharmacol Ther 2019 Apr;49(8):1096-1097

University of Michigan Health System, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15166DOI Listing
April 2019
1 Read

Editorial: differences in sex-based incidence of inflammatory bowel diseases between Asia-Pacific and Western countries - are these due to differences in environment, access to healthcare, or pathophysiology?

Authors:
Simon S M Chan

Aliment Pharmacol Ther 2019 Apr;49(8):1098-1099

Department of Gastroenterology, Norfolk & Norwich University Hospitals NHS Trust, Norwich, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15203DOI Listing
April 2019
1 Read

Editorial: diastolic dysfunction seems not to be decisive for survival after transjugular intrahepatic portosystemic stent-shunt.

Aliment Pharmacol Ther 2019 Apr;49(8):1101-1102

Department of Internal Medicine I, University Clinic Frankfurt, Frankfurt, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15221DOI Listing
April 2019
1 Read

Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non-alcoholic fatty liver disease.

Aliment Pharmacol Ther 2019 Apr;49(8):1092-1093

Section of Clinical Biochemistry, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15208DOI Listing
April 2019
3 Reads

Editorial: direct-acting antivirals decrease the frequency of diabetes complications in patients with chronic hepatitis C.

Aliment Pharmacol Ther 2019 Apr;49(8):1094-1095

Service de médecine digestive et hépatobiliaire, CHU Clermont Ferrand, Clermont Ferrand, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15152DOI Listing
April 2019
1 Read

Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non-alcoholic fatty liver disease - authors' reply.

Aliment Pharmacol Ther 2019 Apr;49(8):1093-1094

Liver Unit/Division of Integrative Systems Medicine and Digestive Disease, Faculty of Medicine, St Mary's Hospital Campus, Imperial College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15215DOI Listing
April 2019
1 Read

Editorial: sarcopenia in liver transplantation-our weakest patients may need the strongest push.

Aliment Pharmacol Ther 2019 Apr;49(8):1100-1101

Division of Hepatology, Department of Medicine Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15204DOI Listing
April 2019
1 Read

Letter: low FODMAP diet-directions for future research.

Aliment Pharmacol Ther 2019 Apr;49(8):1107-1108

Department of Paediatrics, University of Otago (Christchurch), Christchurch, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15175DOI Listing
April 2019
1 Read

Editorial: biomarker predictors of non-response to TNFα antagonists - the quest continues. Authors' reply.

Aliment Pharmacol Ther 2019 Apr;49(8):1091-1092

KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15212DOI Listing
April 2019
1 Read
5.727 Impact Factor

Editorial: biomarker predictors of non-response to TNFα antagonists-the quest continues.

Aliment Pharmacol Ther 2019 Apr;49(8):1089-1090

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15198DOI Listing
April 2019
1 Read

Letter: vitamin D deficiency and autoimmune hepatitis - from research to treatment.

Aliment Pharmacol Ther 2019 Apr;49(8):1103

Department of Cardiology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15147DOI Listing
April 2019
1 Read

Letter: the low FODMAP diet is not the only diet for IBS.

Aliment Pharmacol Ther 2019 Apr;49(8):1108-1109

Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15176DOI Listing
April 2019
1 Read

Editorial: should we abandon HCV genotype testing? Maybe.

Aliment Pharmacol Ther 2019 Apr;49(8):1097-1098

Division of Internal Medicine and Hepatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15194DOI Listing
April 2019
1 Read

Letter: vitamin D deficiency and autoimmune hepatitis - from research to treatment-authors' reply.

Aliment Pharmacol Ther 2019 Apr;49(8):1104-1105

Division of Gastroenterology & Liver Unit, University of Alberta Hospital, Edmonton, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15154DOI Listing
April 2019
1 Read

Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply.

Authors:
Chien-Hung Chen

Aliment Pharmacol Ther 2019 Apr;49(8):1106-1107

Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15183DOI Listing
April 2019
1 Read

Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients.

Aliment Pharmacol Ther 2019 Apr;49(8):1105-1106

Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15150DOI Listing
April 2019
2 Reads

Letter: the end of duodenal biopsies in coeliac disease?

Aliment Pharmacol Ther 2019 Apr;49(8):1110-1111

Gastroenterology Department, Mater Dei Hospital, Tal Qroqq, Malta.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15202DOI Listing
April 2019
1 Read

Letter: the end of duodenal biopsies in coeliac disease? Authors' reply.

Aliment Pharmacol Ther 2019 Apr;49(8):1112

Celiac Disease Research Centre, Tampere University and Tampere University Hospital, Tampere, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15220DOI Listing
April 2019
1 Read

Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis.

Aliment Pharmacol Ther 2019 Mar 25. Epub 2019 Mar 25.

Department of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, AG&M research institute, Amsterdam, The Netherlands.

Background: Off-label prescribing is encountered across various fields of medicine and creates alternative treatment options, but is associated with unknown safety risks. The use of off-label drugs for the treatment of patients with inflammatory bowel diseases (IBD) has not been characterised before.

Aim: To assess the proportion and characteristics of off-label prescribing for IBD in tertiary care centres in the Netherlands. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15229DOI Listing
March 2019
1 Read

Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.

Aliment Pharmacol Ther 2019 May 25;49(9):1223-1229. Epub 2019 Mar 25.

Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Vic., Australia.

Background: Global targets to eliminate hepatitis C (HCV) might be met by sustained treatment uptake.

Aim: To describe factors facilitating HCV treatment uptake and potential challenges to sustaining treatment levels after universal access to direct-acting anti-virals (DAA) across Australia.

Methods: We analysed national Pharmaceutical Benefits Scheme data to determine the number of DAA prescriptions commenced before and after universal access from March 2016 to June 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15210DOI Listing
May 2019
1 Read

Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.

Aliment Pharmacol Ther 2019 Mar 20. Epub 2019 Mar 20.

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.

Background: 5-aminosalicylic acid (5-ASA) is the first-line therapy for ulcerative colitis (UC). 5-ASA acts locally in the colonic mucosa by numerous proposed mechanisms, and is metabolised by N-acetyltransferase (NAT). Large variations in mucosal 5-ASA concentrations have been reported, but the underlying mechanisms are not understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15227DOI Listing
March 2019
1 Read